70090-69-6Relevant articles and documents
Ruthenium-Catalyzed Propargylic Reduction of Propargylic Alcohols with Hantzsch Ester
Ding, Haowei,Sakata, Ken,Kuriyama, Shogo,Nishibayashi, Yoshiaki
supporting information, p. 2130 - 2134 (2020/06/08)
Ruthenium-catalyzed propargylic reduction of propargylic alcohols bearing a terminal alkyne moiety is accomplished by using Hantzsch ester as a nucleophilic hydride source. A variety of secondary and tertiary propargylic alcohols are reduced to the corresponding propargylic reduced products such as 1-alkynes in excellent yields. Some mechanistic studies indicate that ruthenium-allenylidene complexes may work as key reactive intermediates.
Removal of human ether-à-go-go related gene (hERG) K+ channel affinity through rigidity: A case of clofilium analogues
Louvel, Julien,Carvalho, Jo?o F.S.,Yu, Zhiyi,Soethoudt, Marjolein,Lenselink, Eelke B.,Klaasse, Elisabeth,Brussee, Johannes,Ijzerman, Adriaan P.
, p. 9427 - 9440 (2014/01/06)
Cardiotoxicity is a side effect that plagues modern drug design and is very often due to the off-target blockade of the human ether-à-go-go related gene (hERG) potassium channel. To better understand the structural determinants of this blockade, we design
An efficient synthesis of isotope-labeled PD0331179 and its labeled metabolite
Zhang, Yinsheng
, p. 419 - 422 (2013/01/15)
4-[1-Methyl-2,4-dioxo-6-(3-phenyl-prop-1-ynyl)-1,4-dihydro-2H-quinazolin-3- ylmethyl]-benzoic acid, PD0331179, was under investigation as a matrix metalloproteinase-13 inhibitor. 14C-labeled and 2H-labeled PD0331179 and its 2/s